Selank

Selank Research Peptide: Comprehensive Laboratory Guide

For professional laboratory research only. Not for human or veterinary use. Not for food, supplement, cosmetic, household, diagnostic, or therapeutic use.

Overview

Selank research peptide is a synthetic linear heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated TKPRPGP. Its N-terminal four residues reproduce the complete sequence of tuftsin, while its C-terminal Pro-Gly-Pro segment places it among the short glyproline-containing regulatory peptides. PubChem records Selank as CID 11765600, with the neutral molecular formula C₃₃H₅₇N₁₁O₉ and an average molecular mass of 751.9 g/mol.^[1]

Published Selank literature spans peptide chemistry, radioligand binding, brain gene-expression studies, neurochemical measurements, proteolysis, immune-related transcription, behavioral models, and a small number of human investigations. Much of that evidence comes from animal or ex vivo systems, and several frequently repeated mechanism claims remain hypotheses rather than receptor-level conclusions. The peptide should therefore be treated as an experimental probe whose effects depend on model, matrix, exposure, analytical identity, and study design—not as a validated treatment or a predictable substitute for an endogenous pathway.

The most developed mechanistic hypothesis concerns the GABAergic system. A review of radioligand experiments reported concentration- and subtype-dependent changes in [³H]GABA binding and interpreted them as possible allosteric modulation, while a rat frontal-cortex study found rapid changes in transcripts involved in GABAergic and broader neurotransmission.^[3][4] These observations are useful for forming testable questions, but binding displacement and mRNA changes do not by themselves establish a defined receptor-binding site, functional ion-channel modulation, or a causal behavioral mechanism. Orthogonal assays are essential.

Molecular identity and physicochemical profile

Identity numbers describe a defined molecular entity, not every commercial preparation. The formula and mass above apply to the neutral parent sequence. PubChem has a separate record for Selank diacetate, in which two acetic-acid components change the overall formula and average mass.^[2] A hydrated solid, another salt, a formulation, or an isotopically labeled analogue will likewise have a different complete composition. Laboratories should record the exact form stated on the lot-specific CoA and should avoid converting gross vial mass into molar concentration unless peptide content, water, counterion, and other relevant components are known.

The sequence itself offers several analytical handles. Lysine and arginine contribute basic side chains and strongly influence charge-state distribution in positive-ion mass spectrometry. Three proline residues constrain backbone geometry and can affect chromatographic behavior and fragmentation. Threonine adds a hydroxyl group, while the free termini contribute additional acid-base behavior. These structural features help explain why retention, adsorption, recovery, and ionization can change with pH, ionic strength, column chemistry, container surface, and sample matrix. Method performance should be demonstrated experimentally rather than inferred from sequence alone.

Evidence map and mechanistic research themes

1. GABA-associated binding and neurotransmission

The Selank research peptide is often summarized as a GABA_A-receptor positive allosteric modulator, but the underlying evidence requires more careful language. Radioligand work summarized by Vyunova and colleagues found that Selank changed [³H]GABA binding in rat brain-membrane preparations in a concentration-dependent manner. Experiments combining Selank with diazepam or other neuroactive compounds produced interaction patterns that differed from either agent alone, leading the authors to propose subtype-selective allosteric modulation at a site that may differ from conventional benzodiazepine binding.^[3]

That interpretation is a useful hypothesis, not a complete target-validation package. Membrane radioligand binding does not establish direct binding to a purified receptor, a dissociation constant, subunit-selective efficacy, or functional changes in chloride conductance. A robust follow-up design would compare receptor subunit combinations in a defined expression system, include equilibrium and kinetic binding controls, and pair binding with electrophysiology or a validated functional assay. Vehicle, nonspecific-binding, peptide-degradation, and membrane-integrity controls are necessary. Researchers should also compare the intact heptapeptide with relevant fragments to determine whether a signal depends on Selank itself or on products formed during incubation.

2. Rapid gene-expression responses

A rat frontal-cortex experiment evaluated 84 neurotransmission-related genes after exposure to Selank or GABA. The authors reported significant changes in 45 genes at the earlier sampling point and 22 genes at the later point, with a positive correlation between the patterns induced by the two compounds.^[4] The affected panel included receptor subunits, transporters, ion channels, and genes linked to multiple neurotransmitter systems. These results support the idea that Selank can initiate a broad and time-dependent transcriptional response in that model.

Transcript abundance is not equivalent to receptor function or protein abundance. A targeted PCR panel also cannot reveal unmeasured pathways and creates a multiple-testing problem if correction procedures are not prespecified. Replication should include independent cohorts, blinded sample handling, stable reference genes, false-discovery control, and orthogonal confirmation by RNA sequencing or digital PCR. Selected transcripts should be followed with protein-level and functional measurements. Time-course sampling is particularly important because a transient early response may reverse or normalize before a later endpoint.

3. Monoamine metabolism and model dependence

Animal studies have examined serotonin, noradrenaline, dopamine, and their metabolites after Selank exposure. In a PCPA-perturbed rat model, Selank and tuftsin did not produce identical effects: the heptapeptide altered serotonin metabolism in the brain stem under the experimental conditions, whereas tuftsin showed a different regional pattern.^[5] Other comparative work has reported strain-dependent patterns, illustrating that genotype and baseline behavioral phenotype can shape the readout.

These findings do not establish that Selank directly binds a serotonin, dopamine, or noradrenaline receptor. Tissue concentrations and metabolite ratios can reflect synthesis, vesicular storage, release, reuptake, degradation, perfusion, stress, and sampling time. Experiments should therefore measure parent neurotransmitters and major metabolites together, use region-specific dissection, control the interval from handling to tissue freezing, and normalize for recovery. Stable-isotope standards and validated LC-MS/MS methods reduce the uncertainty associated with older bulk biochemical assays. Strain, sex, age, circadian phase, housing, and stress exposure should be treated as prespecified variables rather than background details.

4. BDNF and plasticity-associated endpoints

Brain-derived neurotrophic factor (BDNF) appears in Selank discussions because a rat study reported time- and exposure-dependent changes in hippocampal BDNF expression after peptide exposure.^[6] The reported mRNA and protein responses were not a simple uniform increase. This work supports studying neurotrophin regulation in that animal model, but it does not show that Selank is a direct BDNF agonist, that BDNF mediates every observed effect, or that the finding predicts cognition or neuroprotection in humans.

BDNF analysis is technically sensitive. Total BDNF assays may not distinguish proBDNF from mature BDNF; platelet contamination, region selection, extraction method, and antibody specificity can alter results. A stronger mechanistic design would quantify Bdnf transcripts by promoter, distinguish protein forms where possible, assess TrkB-pathway engagement, and test whether a selective perturbation of BDNF-TrkB signaling changes the phenotype. Behavioral outcomes require blinded scoring, appropriate positive and negative controls, and separation of learning from locomotor, motivational, sensory, or stress-related confounds.

5. Enkephalin-degrading enzymes and peptide-network effects

Selank has also been tested against plasma enzymes that hydrolyze enkephalins. An in vitro study reported concentration-dependent inhibition of enkephalin hydrolysis, with an IC₅₀ of approximately 15 µM under its assay conditions.^[7] This observation motivated the hypothesis that Selank may influence an endogenous regulatory-peptide network indirectly by altering peptide degradation.

Enzyme inhibition measured in plasma is not evidence of receptor agonism, central target engagement, or clinical efficacy. The relevant enzyme mixture, substrate concentration, plasma species, pH, cofactors, and peptide stability all influence the apparent value. Follow-up studies should resolve which peptidases are affected, determine full inhibition curves and kinetics, and verify the result with purified enzymes and orthogonal substrates. Measuring intact Selank, fragments, and enkephalin products in the same experiment can help separate competitive inhibition from general matrix or detection effects.

6. Proteolysis and fragment-aware research

The Selank research peptide can be converted into biologically or analytically relevant fragments. A tritium-labeling study of biodegradation in plasma and rat-brain tissue experiments identified TKPRP, TKP, RP, and GP among the major products under the tested conditions.^[8] This is an important design constraint: an endpoint observed after a long incubation may reflect the intact heptapeptide, one or more fragments, altered peptidase activity, or a combination of these factors. These data do not establish a human half-life, bioavailability, or blood-brain-barrier penetration.

Fragment-aware experiments should sample multiple time points and use a stability-indicating LC-MS method capable of separating the parent from expected truncations. Isotope-labeled internal standards are valuable where available, but label placement must be considered because a labeled fragment can persist after the parent has disappeared. Recovery studies should cover both buffer and biological matrix. When possible, intact Selank and candidate fragments should be tested as separate, identity-confirmed arms at matched molar exposure. This approach turns degradation from an uncontrolled confounder into a testable mechanistic variable.

7. Immune- and inflammation-related transcription

The tuftsin-derived sequence has encouraged studies beyond neuronal systems. Mouse-spleen experiments reported changes in transcripts for cytokines, chemokines, their receptors, and Bcl6-associated regulatory genes after Selank or selected peptide fragments.^[9] The findings show that immune-related endpoints can respond in a specific experimental context; they do not establish that Selank is broadly anti-inflammatory, immunostimulatory, antiviral, or clinically protective.

Immune readouts are especially sensitive to cell composition, handling, circadian timing, microbial status, and stress. Bulk spleen RNA can change because the proportion of cell populations changes, even if expression within each population is constant. Stronger studies combine flow cytometry or single-cell profiling with cell-normalized transcript and protein measurements, include endotoxin testing of the test article, and use sequence-scrambled or fragment controls. Cytokine panels should be interpreted as multivariate patterns rather than as isolated “pro-” or “anti-inflammatory” labels.

Appropriate nonclinical research applications

Within a qualified laboratory and after a task-specific risk assessment, the Selank research peptide may be used to develop and test the following research questions:

• Peptide identity and method development: establish LC-UV, LC-MS, high-resolution MS, amino-acid analysis, and chromatographic methods for the intact TKPRPGP sequence and expected fragments.
• Receptor-binding hypotheses: reproduce or challenge reported GABA-associated radioligand effects using defined receptor preparations and functional confirmation.
• Neurotransmission panels: examine time-dependent transcription or protein changes in validated cellular systems while separating GABA-associated findings from monoamine and stress-response pathways.
• Peptidase and fragment studies: quantify parent disappearance, fragment formation, and effects on selected peptide-degrading enzymes under controlled matrix conditions.
• Neurochemical model comparisons: test whether responses differ by cell type, tissue region, genotype, or experimental stressor using prespecified endpoints and blinded analysis.
• Neurotrophin-associated research: examine BDNF processing and TrkB-pathway readouts without presuming that a correlated behavioral observation proves causality.
• Immune transcription research: assess cell-specific cytokine, chemokine, and regulatory-gene responses with endotoxin controls and appropriate normalization.
• Stability and compatibility programs: evaluate adsorption, oxidation, hydrolysis, freeze-thaw sensitivity, matrix recovery, and container compatibility using stability-indicating analytics.

These are study areas, not validated protocols, clinical indications, or performance claims. Related catalog materials may support orthogonal comparisons: Semax comparison, DSIP research, Pinealon neuropeptide research, the Cerebrolysin peptide mixture, VIP peptide research, and Epithalon peptide research represent distinct test articles. Humanin mitochondrial signaling, the SS-31 mitochondrial peptide, and MOTS-c metabolic signaling belong to different research contexts. None should be treated as a mechanistic substitute for Selank.

Experimental design and assay controls

1. Confirm the test article. Record catalog number, lot number, sequence, chemical form, net content basis, CoA version, storage history, and opening date. Verify identity before interpreting a biological endpoint.
2. Separate parent from fragments. Establish intact-peptide recovery and degradation over the actual experiment. A nominal exposure does not prove that TKPRPGP remains present for the full interval.
3. Use a concentration-time matrix. Select in vitro test ranges from solubility, matrix recovery, assay interference, and viability data generated in the relevant system. Do not transfer a concentration across models without validation.
4. Include vehicle and sequence controls. Use matched vehicle, untreated, process-blank, and where informative scrambled-sequence, tuftsin, Pro-Gly-Pro, or other fragment arms. A related peptide is not automatically a negative control.
5. Build orthogonal target evidence. Pair radioligand binding with a functional receptor assay; pair mRNA with protein and activity; pair BDNF abundance with TrkB engagement; pair cytokine transcripts with secreted proteins and cell-composition measurements.
6. Control analytical artifacts. Check plate binding, tube adsorption, carryover, matrix suppression, peptide aggregation, and signal changes caused by pH or salts. Run spike-recovery and dilution-linearity tests.
7. Predefine statistics. State primary outcomes, exclusions, biological and technical replicate definitions, multiplicity correction, randomization, blinding, and sample-size rationale before data collection.
8. Report boundaries. Identify species, strain, sex, age, cell source, passage, medium, serum status, timing, and analytical method. Avoid converting an association into a receptor mechanism or a model result into a human claim.

A well-controlled comparison may also include AICAR metabolism research as a chemically distinct small-molecule probe or NAD+ metabolism research as a nucleotide/cofactor material. Such links describe catalog relationships only. They do not imply co-use, compatibility, synergy, or a recommended combination. Any multi-compound experiment needs single-compound arms, an interaction model selected in advance, and analytical confirmation that the components remain stable together.

Analytical identity and quality control

Quality assessment for a short synthetic peptide should answer distinct questions: Is the declared sequence present? Are major related substances resolved? What amount of the declared peptide is present? Does the sample remain suitable throughout the analytical workflow? A single chromatographic area percentage cannot answer all of them. For the Selank research peptide, a fit-for-purpose lot package may include:

• Identity by mass spectrometry: high-resolution or otherwise qualified MS matched to the declared chemical form, with theoretical and observed ions, charge states, adduct assignments, mass tolerance, and traceable raw data.
• Sequence confirmation: tandem-MS fragments, amino-acid analysis, or another orthogonal method adequate to distinguish TKPRPGP from truncations, sequence variants, and similarly sized impurities.
• Chromatographic purity: a stability-indicating HPLC or UPLC method with stated column, mobile phases, gradient, detection mode, integration rules, reporting threshold, and system-suitability criteria.
• Peptide content: quantitative amino-acid analysis, calibrated reference-standard HPLC, qNMR, or a justified mass-balance approach. Report assay separately from area purity and gross fill mass.
• Water and counterions: water measurement where relevant and direct or mass-balance assessment of acetate or other declared counterions. These components affect molar calculations.
• Process-related attributes: residual solvents, elemental impurities, and other synthesis-specific tests selected from process knowledge and intended laboratory use.
• Model-specific compatibility: endotoxin, bioburden, or cell-culture compatibility testing only when required by the intended in vitro assay. Such results do not establish sterility or suitability for administration.

Mass-spectrometric interpretation should consider multiply charged ions because lysine, arginine, and the N-terminus can support protonation. Sodium or potassium adducts, in-source fragments, and oxidation-related peaks can complicate a simple nominal-mass comparison. A peptide mass match alone cannot prove residue order or stereochemistry. Conversely, a clean UV chromatogram cannot confirm molecular identity. Combining chromatography with mass and sequence evidence provides a stronger identity assignment.

Reference materials, calibration solutions, sample extracts, and system-suitability mixtures should be documented separately from sale stock. Where absolute quantitation matters, use a traceable standard with known water and counterion content. Include blanks, carryover checks, replicate preparations, and matrix-matched recovery. The lot-specific CoA—not generic website text—should govern any reported purity, content, appearance, or release date.

Handling, stability, and documentation

Handle the Selank research peptide with trained personnel, suitable personal protective equipment, engineering controls, and an institution-approved chemical hygiene plan. Review the current safety data sheet and lot documents before opening the material. Avoid inhalation of dry material, unintended skin or eye contact, environmental release, and contamination of shared work areas. Label all secondary containers clearly and segregate research material from food, medicines, personal products, and clinical supplies.

No universal storage or solution-stability claim should be inferred from the peptide name. Follow the conditions stated for the specific lot. For internal method development, laboratories can run a stability study across the actual container, temperature, light, humidity, matrix, pH, concentration, and handling schedule. Measure the intact parent and relevant degradants with a stability-indicating method. Freeze-thaw behavior, adsorption at low concentration, and compatibility with filters, plates, glass, and polymer tubes should be verified instead of assumed.

Solution preparation for analytical or in vitro research should follow an approved laboratory SOP. Solvent identity, grade, pH, ionic strength, final matrix, concentration basis, mixing history, hold time, and container material belong in the experiment record. A clear distinction is needed between gross mass, peptide content, and molar amount. Do not use a generic vial label or an online purity statement as the only basis for quantitative work.

For reproducibility, retain the supplier CoA, raw chromatograms, mass spectra, receipt record, chain of custody, storage-temperature history, preparation worksheet, instrument sequence, and deviations. Report the exact lot in publications and internal reports. The site’s research-use terms explain the general intended-use boundary, but only the certificate matched to the received lot can support a batch-specific analytical claim.

Evidence and regulatory boundary

The Selank research peptide literature should be read as a heterogeneous evidence map. Rodent membrane, tissue, and behavioral studies establish hypotheses in those systems. They do not demonstrate efficacy, safety, exposure, or a molecular target in humans. The small human publications available through PubMed include a 60-participant comparison with phenazepam and a 62-participant comparison with medazepam; neither provides the large, independently replicated, placebo-controlled evidence base needed for a clinical conclusion.^[10][11] Their scale, reporting detail, comparator designs, language accessibility, and geographic concentration limit generalization. They do not support claims that this catalog material treats anxiety, improves memory, enhances performance, or is safe for self-use.

Database identifiers such as a PubChem CID, CAS number, or UNII identify a substance; they are not evidence that a specific commercial lot is approved, manufactured as a medicine, sterile, clinically effective, or suitable for administration. FDA currently lists Selank acetate among nominated bulk substances for which compounded drugs may pose immunogenicity risk because of potential aggregation and peptide-related impurities, and states that it lacks important information about safety issues from human administration.^[12] This Hanpro product is a laboratory research material, not an FDA-approved drug product, and is not represented as a dietary supplement, food, cosmetic, or veterinary product. References to experimental anxiety, cognition, stress, immune, or neurochemical models describe published research questions only.

Human or animal use, self-experimentation, diagnosis, treatment, prevention, performance enhancement, and personal dosing are outside the intended use. Researchers working under an institutionally authorized protocol remain responsible for ethics review, legal status, occupational safety, and local rules. Nothing on this page is medical advice, a clinical protocol, or a recommendation to administer Selank.

Related research materials and internal navigation

Related catalog materials include other short regulatory peptides, mitochondrial-signaling peptides, and chemically distinct metabolic probes. Similar catalog placement does not establish a shared receptor, equivalent potency, interchangeability, compatibility, or biological synergy. Cross-compound screens need identity-confirmed materials, lot-specific molar calculations, matched controls, and separate stability checks. Internal links are provided only for navigation and research planning.

Frequently asked questions

What is the Selank research peptide?

Selank is a synthetic linear heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The first four residues match tuftsin, and the final Pro-Gly-Pro segment extends that sequence. PubChem records the neutral parent as C₃₃H₅₇N₁₁O₉, average molecular mass 751.9 g/mol, CAS 129954-34-3, and CID 11765600.^[1] Selank diacetate is a distinct database record, and commercial salt, water, or solvent content must be taken from lot documents.^[2]

Is Selank a direct GABA_A receptor agonist?

That conclusion has not been established by the cited evidence. Radioligand experiments reported changes in [³H]GABA binding and proposed allosteric modulation, while a rat study found rapid changes in neurotransmission-related transcripts.^[3][4] Direct binding, a defined site, subunit-selective functional efficacy, and causal links to downstream phenotypes require additional receptor-level and electrophysiological work.

What does the Selank BDNF study show?

A rat study reported context- and time-dependent changes in hippocampal BDNF expression after Selank exposure.^[6] That observation does not prove a direct BDNF mechanism, a general cognitive effect, neuroprotection, or a human benefit. BDNF form, brain region, assay method, and behavioral confounders must be controlled.

Why should Selank fragments be measured?

Biodegradation work identified several products, including TKPRP, TKP, RP, and GP.^[8] If the parent changes during an experiment, a late endpoint may reflect intact Selank, fragments, or altered peptidase activity. A stability-indicating LC-MS time course helps determine what the biological or analytical system was actually exposed to.

What purity or vial content does this page guarantee?

No generic value is asserted here. Purity, peptide assay, water, counterion content, gross fill mass, net peptide content, physical form, and availability are lot- or variant-specific. Consult the selected live product configuration and its matching CoA. An HPLC area percentage alone is not equivalent to identity, net content, sterility, or suitability for a particular assay.

How should a laboratory select an in vitro concentration?

Use institution-approved, model-specific pilot work based on analytical recovery, matrix compatibility, parent stability, assay interference, and cell viability. A concentration reported in one tissue, species, or assay should not be transferred automatically to another. This page does not provide human or animal dosing, administration, or personal-use instructions.

Is this material intended to diagnose, treat, or prevent a condition?

No. It is supplied solely for controlled laboratory research and analytical use. It is not for human or veterinary use, self-experimentation, food, supplements, cosmetics, diagnosis, treatment, prevention, or performance enhancement. Published model findings and database identifiers do not change that intended-use boundary.

References

1. PubChem. Selank, CID 11765600. Compound identity, sequence, formula, molecular mass, and identifiers.
2. PubChem. Selank diacetate, CID 155804769. Distinct diacetate composition, formula, molecular mass, and identifiers.
3. Vyunova TV, et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741.
4. Volkova AA, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26924987.
5. Semenova TP, et al. Comparison of the effects of Selank and tuftsin on serotonin metabolism in rat brain after PCPA pretreatment. Eksp Klin Farmakol. 2009;72(4):6-8. PMID: 19803361.
6. Inozemtseva LS, et al. Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841804.
7. Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. PMID: 11550013.
8. Zolotarev YA, et al. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Bioorg Khim. 2006;32(2):183-191. PMID: 16637290.
9. Kolomin T, et al. Expression of inflammation-related genes in mouse spleen under tuftsin analogue Selank. Regul Pept. 2011;170(1-3):18-23. PMID: 21609736.
10. Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. PMID: 25176261.
11. Zozulia AA, et al. Efficacy and possible mechanisms of Selank in generalized anxiety disorder and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
12. U.S. Food and Drug Administration: current safety-risk information for Selank acetate (TP-7) and the 2020 Tailor Made Compounding warning letter addressing Selank-containing products and unapproved-drug claims.

Research-use-only notice: This page summarizes chemical identity, analytical considerations, and published research to support qualified laboratory planning. It does not provide medical advice or instructions for administration. The product is not intended for human or animal consumption, clinical use, diagnosis, treatment, prevention, or performance enhancement.